Answers are grounded in this paper and cite their sources.
Erlotinib is a human epidermal growth factor receptor / tyrosine kinase inhibitor (EGFR-TKI), which is effective as a first and second-line treatment for patients with advanced stage non-small cell lung cancer (NSCLC) with EGFR mutations.Erlotinib is considered to have a favorable safety profile, few cases of interstitial lung disease (ILD) related to erlotinib have been described.We report a case of a 58-year-old male with stage IV NSCLC treated with erlotinib who developed ILD and died on 55 th day since commencing erlotinib.Respiratory symptoms during treatment with erlotinib should alert clinicians to rule out pulmonary toxicity, early erlotinib withdrawal is crucial.
No takes yet. Share an insight, caveat, or question.
Yanbin Chen (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: